Navigation Links
Insmed and Premacure Cite Study Results Demonstrating Potential Effectiveness of IPLEX(TM) in Preventing Blindness in Premature Infants
Date:9/23/2008

fers the first possible intervention to prevent this blinding disease."

"Our research focuses on promoting neural, vascular and metabolic development in premature infants," said Ann Hellstrom, Professor in Pediatric Ophthalmology, Sahlgrenska Academy, Gothenburg, Sweden. "While in this study we are attempting to identify the benefits of IGF-I for ROP, our findings are also likely to be applicable to many aspects of complications of premature birth and could provide benefits for a lifespan."

"This is a crucial step in the clinical development of a preventative treatment against lifelong severe visual impairment or blindness in infants born preterm," said Jan Borg, CEO of Premacure. "Based in part on these results, we intend to initiate a phase II multicenter trial in the ROP indication during the fourth quarter."

"The ability of IPLEX(TM) to raise serum levels of two key proteins involved in the pathogenesis of ROP safely may offer a more effective preventive option in at-risk infants than the highly invasive and destructive treatment options of laser therapy or cryotherapy that are currently utilized to stem disease progression only," said Geoffrey Allan, President and CEO of Insmed. "We are pleased that researchers at such distinguished universities continue to see promise in IPLEX(TM) in ROP and intend to continue evaluating the drug in this indication. Moreover, these results serve as further evidence of the effectiveness of IPLEX(TM) in potentially treating some of the most under-served therapeutic populations, including Myotonic Muscular Dystrophy and Amyotrophic Lateral Sclerosis."

Clinical Study Results

Low levels of IGF-I are known to contribute to the pathogenesis of ROP. The objectives of this open label, investigator-sponsored clinical study were to determine whether intravenous administration of rhIGFI/rhIGFBP-3 (IPLEX(TM)) could increase serum levels of these proteins in at-risk infants to levels seen in normal infan
'/>"/>

SOURCE Insmed Inc.; Premacure AB
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Insmed to Present at Biosimilars 2008 Conference
2. Insmed to Present at BioPharm Asia 2008 Conference
3. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
4. Insmed CEO to Present at Drug Discovery & Development Conference
5. Insmed to Host Second Quarter 2008 Conference Call
6. Insmed Partners With Bill Thomas, Former House Ways and Means Chairman, as Strategic Advisor
7. Insmed Retains RBC Capital Markets as Strategic Financial Advisor
8. Insmed to Present at Collins Stewart Fourth Annual Growth Conference
9. Insmed to Request Hearing Before NASDAQ Panel to Review NASDAQ Staff Determination
10. Insmed Announces First Quarter 2008 Financial Results
11. Insmed to Present at CBI Follow-On Biologics Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... YORK , July 27, 2015 ... today announced the winners of its annual Klerman ... research by scientists who have been supported by ... career scientists to pursue innovative ideas in neurobiological ... "proof" of concept for the early detection, treatment, ...
(Date:7/27/2015)... , July 27, 2015 IDEXX Laboratories, ... than 8,000 clinics have submitted over 100,000 specimens to ... in just the first 10 days since the breakthrough ... disease (CKD) is a leading cause of suffering and ... submitted specimens are consistent with generally accepted kidney disease ...
(Date:7/26/2015)... ... July 26, 2015 , ... ... VALIDATE® ANEMIA calibration verification / linearity test kit. The VALIDATE® ANEMIA kit contains ... ANEMIA kit is prepared using the CLSI recommended “equal delta” method for linearity ...
(Date:7/24/2015)... 24, 2015 Ryan & Maniskas, LLP ... States District Court for the Northern District of ... that purchased the common stock of Avalanche Biotechnologies, Inc. ("Avalanche" ... 2014 and June 15, 2015, inclusive (the "Class Period"). ... move the Court for appointment as a lead plaintiff of ...
Breaking Biology Technology:Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 2Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 3Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 4Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 5Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 6Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 2Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 3Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 4Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 5Maine Standards Company, LLC Announces Release of VALIDATE® ANEMIA Calibration Verification / Linearity Test Kit 2Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Avalanche Biotechnologies, Inc. 2Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Avalanche Biotechnologies, Inc. 3
... ExL Pharma, Cision and the PRSA have,joined together ... relations executives the first Pharmaceutical Public Relations,Symposium in ... event will cover the key issues and challenges ... under ongoing political and media scrutiny,most notably as ...
... pharma industry is,not at a standstill: it has changed ... companies, profits, biological drugs are,now making their presence felt. ... impact, biologicals are providing the current focus for novel,discovery. ... rules,for their development are different and they are often ...
... (Nasdaq: JAZZ ) announced today that Nathaniel M.,Zilkha has ... 2007. The Company also announced that Adam H. Clammer has,resigned ... Mr. Zilkha is a Principal at Kohlberg Kravis Roberts & ... industry team. Prior to joining KKR,earlier this year, Mr. Zilkha ...
Cached Biology Technology:Leading Pharmaceutical Communication Executives Gather for the 1st Annual Pharmaceutical Public Relations Symposium 2Updated Drug Development Scrip Report Responds to the Pharma Industry's Major Changes 2
(Date:6/30/2015)... June 30, 2015 Genisphere announced ... CEO to help further develop Genisphere,s therapeutics capabilities and ... experience, having spent much of the last 25 years ... Baxter Bioscience, and Johnson & Johnson. Tom started his ... and Biotech Corporate Finance. He graduated from Dartmouth College ...
(Date:6/25/2015)... N.J. , June 25, 2015  TAKE Solutions ... a patent by the United States Patent and Trademark ... Standardization". This process leverages TAKE Solutions, Clinical Accelerators to ... over 50% (when compared to standardization without the accelerators), ... At the heart of ...
(Date:6/24/2015)... , June 24, 2015 Biometry authentication ... emerging biometric password solution one face in. ... one face in, entering the expanding ... and affordable multifactor-authentication biometric answer to the password ... provided in partnership with KeyLemon, one face in ...
Breaking Biology News(10 mins):Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3TAKE Solutions Awarded Patent By USPTO 2KeyLemon Announces Partnership With Biometric Password Solution onefacein 2
... PA, February 20, 2013 A study published in the ... has determined that there is increasing evidence of a connection ... and dairy products, and that medical nutrition therapy (MNT) can ... 17 million Americans suffer from acne, mostly during their adolescent ...
... 2013) New findings by Columbia researchers suggest ... may be a second necessary factor for the development ... Alzheimer,s disease focus on the accumulation of amyloid plaque ... for Research on Alzheimer,s Disease and the Aging Brain, ...
... Identifying areas of malarial infection risk depends ... average monthly temperatures, according to a team of ... apply to environmentally temperature-dependent organisms other than the ... of several of the essential mosquito and parasite ...
Cached Biology News:Increasing evidence links high glycemic index foods and dairy products to acne 2New approach alters malaria maps 2
HSPBP1 Antibody...
... RACE (rapid amplification of cDNA ends) technique ... 5' and 3' cDNA ends. The GeneRacer ... Transcriptase (RT) for improved amplification of the ... mRNA. The RNase H portion of SuperScript ...
1, 2 or 8 PreMixes are included as part of the FailSafe™ PCR System....
Reactivity: Human...
Biology Products: